An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...
A new therapy that combines two existing drugs shows promise for patients with inflammatory bowel disease who have exhausted ...
A new combination drug therapy could help people with inflammatory bowel disease (IBD) for whom other medicines have stopped ...
Ulcerative colitis treatment drug Omvoh, from Eli Lilly, was linked to sustained clinical remission after 4 years, according to new trial data. Image credit: Plexi Images/GHI/UCG/Universal Images ...
LUCENT-3 trial open-label extension data show 63.5% of adults with ulcerative colitis administered mirikizumab (Omvoh) who ...
Even with biologics changing the treatment paradigm for ulcerative colitis more than 2 decades ago, patients have a similar ...
Treatment failure occurs when an ulcerative colitis medication isn’t helping symptoms. Most important, know that it’s not your fault. Learn what to do next.
Ulcerative colitis is more than a digestive condition — it’s a daily challenge of balancing symptoms, treatment, and mental well-being. New research is uncovering how genetics, gut bacteria, and ...
Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with UC, including those in Ontario and ...
How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD). It causes painful sores and inflammation deep inside your colon and rectum. That can lead to hard-to-manage symptoms like ...